PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Puma Biotechnology, Inc. (PBYI)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US74587V1070

CUSIP

74587V107

Sector

Healthcare

IPO Date

Apr 24, 2012

Highlights

Market Cap

$141.37M

EPS (TTM)

$0.47

PE Ratio

6.13

PEG Ratio

0.03

Total Revenue (TTM)

$171.39M

Gross Profit (TTM)

$120.91M

EBITDA (TTM)

$30.38M

Year Range

$2.23 - $7.15

Target Price

$4.33

Short %

7.16%

Short Ratio

4.23

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
PBYI vs. VOO PBYI vs. SPY PBYI vs. ^GSPC
Popular comparisons:
PBYI vs. VOO PBYI vs. SPY PBYI vs. ^GSPC

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Puma Biotechnology, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-10.00%0.00%10.00%20.00%30.00%40.00%SeptemberOctoberNovemberDecember2025February
6.64%
9.31%
PBYI (Puma Biotechnology, Inc.)
Benchmark (^GSPC)

Returns By Period

Puma Biotechnology, Inc. had a return of -5.57% year-to-date (YTD) and -57.58% in the last 12 months. Over the past 10 years, Puma Biotechnology, Inc. had an annualized return of -34.88%, while the S&P 500 had an annualized return of 11.31%, indicating that Puma Biotechnology, Inc. did not perform as well as the benchmark.


PBYI

YTD

-5.57%

1M

-3.03%

6M

6.67%

1Y

-57.58%

5Y*

-26.78%

10Y*

-34.88%

^GSPC (Benchmark)

YTD

4.46%

1M

2.46%

6M

9.31%

1Y

23.49%

5Y*

13.03%

10Y*

11.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of PBYI, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-5.25%-5.57%
20248.55%32.34%-14.79%-4.34%-24.06%-15.32%9.97%-30.26%2.00%11.76%18.95%-10.03%-29.56%
20231.65%-10.23%-19.95%-13.27%25.00%5.37%2.55%0.28%-27.55%-6.46%58.54%11.03%2.36%
2022-19.08%-6.50%25.22%-18.06%-17.80%46.91%2.81%-8.53%-11.57%-8.02%107.34%-6.42%39.14%
202114.42%-15.16%-2.41%1.44%7.00%-12.99%-18.08%0.66%-7.40%-27.25%-39.22%-1.94%-70.37%
2020-10.17%36.83%-21.52%19.08%1.59%2.15%-1.15%-0.19%-1.94%-17.05%34.41%-8.80%17.26%
201937.00%-0.25%39.48%-17.20%-53.95%-14.06%-24.08%11.40%0.14%-36.83%39.56%-7.80%-57.00%
2018-32.37%-2.24%4.13%-6.32%-16.94%11.71%-18.60%-8.72%4.32%-19.19%-37.27%-12.44%-79.41%
20175.54%13.27%1.36%9.14%88.42%14.25%8.75%-2.68%29.46%6.30%-16.81%-6.66%221.99%
2016-46.76%7.28%-34.41%4.49%23.13%-21.17%67.47%18.56%13.36%-42.88%12.40%-28.69%-60.84%
201511.52%0.91%10.84%-23.52%8.23%-40.27%-22.40%1.46%-18.02%9.37%-8.64%4.12%-58.58%
201414.18%-1.65%-10.42%-27.46%1.18%-13.65%235.94%17.50%-8.42%5.04%-9.41%-16.63%82.82%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PBYI is 11, meaning it’s performing worse than 89% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of PBYI is 1111
Overall Rank
The Sharpe Ratio Rank of PBYI is 99
Sharpe Ratio Rank
The Sortino Ratio Rank of PBYI is 99
Sortino Ratio Rank
The Omega Ratio Rank of PBYI is 1010
Omega Ratio Rank
The Calmar Ratio Rank of PBYI is 1212
Calmar Ratio Rank
The Martin Ratio Rank of PBYI is 1717
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Puma Biotechnology, Inc. (PBYI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for PBYI, currently valued at -0.78, compared to the broader market-2.000.002.00-0.781.74
The chart of Sortino ratio for PBYI, currently valued at -1.10, compared to the broader market-4.00-2.000.002.004.006.00-1.102.35
The chart of Omega ratio for PBYI, currently valued at 0.87, compared to the broader market0.501.001.502.000.871.32
The chart of Calmar ratio for PBYI, currently valued at -0.59, compared to the broader market0.002.004.006.00-0.592.61
The chart of Martin ratio for PBYI, currently valued at -1.15, compared to the broader market0.0010.0020.0030.00-1.1510.66
PBYI
^GSPC

The current Puma Biotechnology, Inc. Sharpe ratio is -0.78. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Puma Biotechnology, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-0.78
1.74
PBYI (Puma Biotechnology, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Puma Biotechnology, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-98.95%
0
PBYI (Puma Biotechnology, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Puma Biotechnology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Puma Biotechnology, Inc. was 99.40%, occurring on May 11, 2022. The portfolio has not yet recovered.

The current Puma Biotechnology, Inc. drawdown is 98.95%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.4%Sep 19, 20141925May 11, 2022
-60.7%Jan 22, 201493Jun 4, 201434Jul 23, 2014127
-39.73%Sep 10, 201346Nov 12, 201316Dec 5, 201362
-21.43%Apr 27, 201226Jun 4, 201235Aug 20, 201261
-19.73%Oct 24, 201222Nov 27, 201233Jan 15, 201355

Volatility

Volatility Chart

The current Puma Biotechnology, Inc. volatility is 10.72%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%SeptemberOctoberNovemberDecember2025February
10.72%
3.07%
PBYI (Puma Biotechnology, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Puma Biotechnology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Puma Biotechnology, Inc. compared to its peers in the Biotechnology industry.


PE Ratio
100.0200.0300.0400.0500.0600.06.1
The chart displays the price to earnings (P/E) ratio for PBYI in comparison to other companies of the Biotechnology industry. Currently, PBYI has a PE value of 6.1. This PE ratio falls in the average range for the industry.
PEG Ratio
-1,000.0-800.0-600.0-400.0-200.00.00.0
The chart displays the price to earnings to growth (PEG) ratio for PBYI in comparison to other companies of the Biotechnology industry. Currently, PBYI has a PEG value of 0.0. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Puma Biotechnology, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab